Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT03467854 |
| Other study ID # |
AAAR7200 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 1, 2019 |
| Est. completion date |
December 2024 |
Study information
| Verified date |
February 2024 |
| Source |
Columbia University |
| Contact |
Darryl Abrams, MD |
| Phone |
212-305-4141 |
| Email |
da2256[@]cumc.columbia.edu |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study is designed to provide preliminary data to determine if concentrations of
piperacillin/tazobactam change in patients with severe respiratory failure receiving
extracorporeal membrane oxygenation (ECMO). The investigators hypothesize that patients will
have significant changes in concentration measurements, specifically an increased clearance
rate and increased volume of distribution, during ECMO as compared to critically ill
patients.
Description:
In a healthy patient, the lungs provide oxygen to the blood and remove carbon dioxide.
However, in patients with severe lung failure, blood may not adequately be delivered to the
lungs, or the lungs may not adequately supply blood with oxygen. In this case, patients may
require assistance from a machine to help provide this oxygen. Extracorporeal membrane
oxygenation (ECMO) is a device that acts as an artificial lung, allowing the patient to
recover from their illness. Patients receiving support from ECMO are often put in a medically
induced coma while their lungs heal. Certain drugs may stick to the internal surfaces of the
machine; therefore leading to decreased concentrations. Patients receiving ECMO often require
antimicrobials to treat severe infections. However, little data exist concerning the likely
changes in drug concentrations from drug circuit interactions in adult patients receiving
ECMO.
